Allergan, Editas form eye drug alliance | Chemical & Engineering News
Volume 95 Issue 12 | p. 13 | Concentrates
Issue Date: March 20, 2017

Allergan, Editas form eye drug alliance

Department: Business
Keywords: drug discovery, CRISPR, ophthalmics, Editas Medicine

Allergan and Editas Medicine have established an ophthalmic-disease-related R&D alliance. Allergan will pay $90 million up front to access up to five early-stage CRISPR genome-editing programs at Editas. Included is Editas’s lead program for Leber congenital amaurosis, a rare, inherited retinal degenerative disease. Allergan will be responsible for developing and commercializing any resulting products. Editas could codevelop up to two.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment